Vicore Pharma Holding AB (publ) (STO:VICO)

Sweden flag Sweden · Delayed Price · Currency is SEK
7.48
+0.08 (1.08%)
Mar 25, 2025, 1:50 PM CET
-50.07%
Market Cap 1.75B
Revenue (ttm) 109.35M
Net Income (ttm) -168.63M
Shares Out 234.58M
EPS (ttm) -1.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 54,088
Average Volume 332,388
Open 7.40
Previous Close 7.40
Day's Range 7.36 - 7.58
52-Week Range 6.92 - 24.10
Beta 0.56
RSI 41.26
Earnings Date Feb 27, 2025

About Vicore Pharma Holding AB

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases. It develops C21, an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. The company is also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 29
Stock Exchange Nasdaq Stockholm
Ticker Symbol VICO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.